ESMO 2025 preview – a bemarituzumab reckoning approaches
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
Neither Arvinas nor Pfizer now wants vepdegestrant
So who else could be interested in the oestrogen degrader?
Astra and J&J tussle over first-line lung
The companies clash over survival curve similarities – and differences.
World Lung 2025 – crossing curves in lung cancer
Tolerability could decide first-line therapy in EGFRm disease.
The month ahead: September’s upcoming events
It’s a new term for biotech and its investors.
FDA doubles down on overall survival
New draft guidance could see the agency getting ever stricter.
Gilead gets into in vivo Car-T
Interius, one of the most advanced players, will cost $350m.
Astellas and Amgen join the pan-KRAS push
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
Astra’s Neogene investment nosedives
NT-125 is discontinued, while two key Datroway readouts are delayed.
